To assess SAR228810 in patients with Alzheimer's disease - Guy's EC

• Research type

  Research Study

• Full title

  A multi-center, parallel-group, double-blind, placebo-controlled single and multiple dose escalation study to assess the safety and tolerability and the pharmacokinetic properties of SAR228810 given as IV infusion or as SC injection in patients with mild to moderate Alzheimer’s Disease

• IRAS ID

  101180

• Contact name

  Darren Wilbraham

• Sponsor organisation

  Sanofi-Aventis

• Eudract number

  2011-002910-35

• Research summary

  For Alzheimer??s disease there are currently only treatments available that relieve the symptoms of the disease to some extent. No medications are really combating the disease to slow down or stop the progression. Therefore, a lot of research is being performed on new medications for this disease. SAR228810 is a new investigational medication in development for the treatment of Alzheimer??s disease. The purpose of this research study is to assess the safety, tolerability and the way the body handles SAR228810 in patients with mild to moderate Alzheimer??s Disease. The study is designed to find out the highest dose of SAR22810 that may be given safely to Alzheimer's patients, either by intravenous infusion (given by drip in a vein) or subcutaneous (under the skin) injection.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  12/LO/0174

• Date of REC Opinion

  30 Apr 2012

• REC opinion

  Further Information Favourable Opinion